Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Icaritin
Sponsor: Chinese Academy of Medical Sciences
Collaborators: Beijing Shenogen Biomedical Co., Ltd